



4-25-05

15N

Receipt

CASE ON/4-32331A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 524612275US

Express Mail Label Number

April 22, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

CARLOS GARCIA-ECHEVERRIA

INTERNATIONAL APPLICATION NO: PCT/EP03/00803

Art Unit: 1616

FILED: 27 JANUARY 2003

U.S. APPLICATION NO: 10/502,533

35 USC §371 DATE: JANUARY 20, 2005

FOR: BETA-HOMOLYSINE CONJUGATES AND THEIR USE AS  
TRANSPORT ENHANCER

**Mail Stop: PCT**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**LETTER CORRECTING OFFICIAL FILING RECEIPT**

Sir:

The official filing receipt received in the above-identified application erroneously lists the **Applicant(s)** information. There is only one inventor in this case. Enclosed is a copy of the title page of the International Publication **WO 03/063 910** showing this to be true. Please issue a corrected filing receipt listing the applicants' information as follows:

-- **Applicant(s)**


Carlos Garcia-Echeverria, Basel, SWITZERLAND; --


A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898  
LTM:dd  
Encls.:  
Date: April 21, 2005

  
Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,533	01/20/2005	1616	1050	ON/4-32331A		16	2

001095  
NOVARTIS  
CORPORATE INTELLECTUAL PROPERTY  
ONE HEALTH PLAZA 104/3  
EAST HANOVER, NJ 07936-1080

CONFIRMATION NO. 7484

## FILING RECEIPT



\*OC000000015176610\*

LTM

Date Mailed: 02/16/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Olivier Loiseleur, Saint-Louis, FRANCE;  
Daniel Kaufmann, Therwil, SWITZERLAND;  
Stephan Abel, Weill am Rhein, GERMANY;  
Hans-Michael Burger, Allschwil, SWITZERLAND;  
Mark Meisenbach, Durmenach, FRANCE;  
Beat Schmitz, Allschwil, SWITZERLAND;  
Gottfried Sedelmeier, Schallstadt, GERMANY;

*Carlos Garcia-Echeverria, Basel, Switzerland*

## Power of Attorney:

Lydia McNally-36214

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/00803 01/27/2003

## Foreign Applications

UNITED KINGDOM 02018810 01/28/2002  
UNITED KINGDOM 02028751 02/07/2002

Projected Publication Date: 05/26/2005

Non-Publication Request: No



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
WO 03/063910 A2(51) International Patent Classification<sup>7</sup>: A61K 47/48

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP03/00803

(22) International Filing Date: 27 January 2003 (27.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0201881.0 ✓ 28 January 2002 (28.01.2002) GB  
0202875.1 ✓ 7 February 2002 (07.02.2002) GB(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.(71) Applicant (*for all designated States except AT, US*): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

## Published:

— without international search report and to be republished upon receipt of that report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): GARCIA-ECHEVERRIA, Carlos [ES/CH]; Engelgasse 126, CH-4052 Basel (CH).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/063910 A2

(54) Title:  $\beta$ -HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER

(57) Abstract: The present invention relates to a conjugate that comprises a) at least one compound to be delivered into or across a biological barrier, b) a delivery-enhancing transporter comprising at least 4  $\beta$ -homolysine residues, especially between 4 and 25  $\beta$ -homolysine residues, c) optionally a linker between the components a) and b), and d) optionally a labelling unit; to the salts of such conjugates; to a pharmaceutical composition comprising said conjugate; to a method for delivery of a compound into or across a biological barrier, the method comprising contacting the barrier with said conjugate; and to a process for the preparation of certain conjugates.